6533b826fe1ef96bd12852d5

RESEARCH PRODUCT

Continuous Intravenous Administration of Granulocyte-Colony-Stimulating Factors—A Breakthrough in the Treatment of Cancer Patients with Febrile Neutropenia

Calin CainapOvidiu BalacescuAlina Simona BereanuCristina CrisanAndra MesterAnne-marie ConstantinLaura PopIrina DicuCrişan OvidiuSânziana Cetean-gheorghePatriciu Achimas-cadariuDaniel Corneliu LeucutaAdina StanDoina PiciuAlexandra GhermanCatalin VladSimona CainapLoredana Balacescu

subject

Malemedicine.medical_specialtyMedicine (General)Side effectmedicine.medical_treatmentNeutropeniaG-CSFfebrilechemotherapyGastroenterologyArticleProcalcitoninR5-920NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansneutropeniacancerProspective StudiesProspective cohort studyFebrile NeutropeniaChemotherapybiologybusiness.industryStandard treatmentC-reactive proteinGeneral Medicinemedicine.diseasebiology.proteinAdministration IntravenousFemalebusinessFebrile neutropeniaGranulocytes

description

(1) Background: Febrile neutropenia (FN) remains one of the most challenging problems in medical oncology and is a very severe side effect of chemotherapy. Its late consequences, when it is recurrent or of a severe grade, are dose reduction and therapy delays. Current guidelines allow the administration of granulocyte-colony-stimulating factors (G-CSF) for profound FN (except for the case when a pegylated form of G-CSF is administrated with prophylactic intention) in addition to antibiotics and supportive care. (2) Methods: This is a prospective study that included 96 patients with confirmed malignancy, treated with chemotherapy, who developed FN during their oncological therapy, and were hospitalized. They received standard treatment plus a dose of G-CSF of 16 µg/Kg/day IV continuous infusion. (3) Results: The gender distribution was almost symmetrical: Male patients made up 48.96% and 51.04% were female patients, with no significance on recovery from FN (p = 1.00). The patients who received prophylactic G-CSF made up 20.21%, but this was not a predictive or prognostic factor for the recovery time from aplasia (p = 0.34). The median chemotherapy line where patients with FN were included was two and the number of previous chemotherapy cycles before FN was three. The median serological number of neutrophils (PMN) was 450/mm3 and leucocytes (WBC) 1875/mm3 at the time of FN. Ten patients possess PMN less than 100/mm3. The median time to recovery was 25.5 h for 96 included patients, with one failure in which the patient possessed grade 5 FN. Predictive factors for shorter recovery time were lower levels of C reactive protein (p &lt

10.3390/medicina57070675https://www.mdpi.com/1648-9144/57/7/675